UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer ...
Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness ...
Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown ...
Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional patent application on this treatment method. Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...
Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19. Each of these new antibodies bind to different ...
Jackson Center, PA, May 19, 2021 – Halberd Corporation (OTC-PINK: "HALB") was featured in a recent MarketWatch article, “New Approaches to Covid-19 Treatment Enter the Picture,” along with six other notable biotechnology companies. As stated in the article, “The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE:PFE), BioNTech ...
Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...
Jackson Center, PA, April 26, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Treating and Curing Covid-19 Infection Utilizing a Laser.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William ...
Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties. This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...
Jackson Center, PA, March 18, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously. William A. ...